Speeding the development of new therapies and diagnostics for glaucoma patients

February 6, 2015

The Palace Hotel • San Francisco, CA

Presented by

GLAUCOMA RESEARCH FOUNDATION

Follow the meeting on Twitter: #Glaucoma360
Glaucoma Research Foundation thanks the following sponsors for their generous support:

**Platinum Sponsors**

![Allergan Logo]

**Gold Sponsors**

- Alcon
- Bausch + Lomb
- Genentech (A Member of the Roche Group)
- Lumenis

**Silver Sponsors**

- Abbott Medical Optics
- Zeiss
- CARL ZEISS MEDITEC
- DSM
- Haag-Streit USA
- The Link Family
- New World Medical, Inc.
- Ora

**Bronze Sponsors**

- Akorn, Inc.
- Beaver-Visitec International, Inc.
- CenterVue, Inc.
- Ellex
- Glaukos Corporation
- Heidelberg Engineering, Inc.
- Icare USA
- Iridex
- Mobius Therapeutics, LLC
- Nidek, Inc.
- NovaBay Pharmaceuticals, Inc.
- Ocular Therapeutix, Inc.
- Ophthalmic Mutual Insurance Company
- Optovue, Inc.
- Reichert, Inc.
- Shire
- TearLab Corporation
Welcome

It is our sincere pleasure to welcome you to the 4th Annual Glaucoma 360: New Horizons Forum. This catalyst meeting, hosted by Glaucoma Research Foundation, highlights the many unmet medical needs that remain in the field of glaucoma and brings together the essential elements needed to advance the development of new ideas into clinical practice to prevent and manage the disease more effectively. With the overwhelming success of our previous meetings, this annual forum continues to grow and provide the ultimate opportunity for collaboration and networking to advance new concepts to reality for glaucoma patients.

Our meeting objectives today are to:

• Bring together nationally and internationally respected leaders in medicine, science, business, venture capital, and the FDA to present and discuss new and emerging ideas in the field of glaucoma therapy.

• Facilitate collaboration between these essential groups in order to accelerate the development and approval of the next generation of therapies and diagnostic devices.

• Broaden our understanding of glaucoma from various sectors engaged in research and development to advance new and effective options to help patients preserve their sight.

Today would not be possible without the generous and selfless contributions of so many including: members of our Advisory Board and Program Committee who have volunteered their time to build an outstanding agenda; our committed sponsors who have helped to underwrite this event; our speakers, presenters, and panelists who are ready to share their expertise and unique perspective; our attendees; the support of our Board of Directors and staff at Glaucoma Research Foundation; and the hard working team at The Palace Hotel.

We are honored to have your involvement in this important endeavor to speed the development of new glaucoma drugs, devices, and drug delivery systems. Proceeds from Glaucoma 360 events will support Glaucoma Research Foundation’s sight-saving endeavors like Catalyst for a Cure, which aim to uncover new diagnostic and treatment options and find a cure for glaucoma. Together, we can truly make a difference for people living with glaucoma.

Thank you for your partnership in this important endeavor.

Adrienne Graves, PhD
Co-Founder, Co-Chair
New Horizons Forum
Director,
Glaucoma Research Foundation

Andrew G. Iwach, MD
Co-Founder, Co-Chair
New Horizons Forum
Board Chair,
Glaucoma Research Foundation
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Details</th>
</tr>
</thead>
</table>
| 7:30 – 8:00 am | Breakfast and Exhibits                                              | Morning Master of Ceremonies  
Joel Schuman, MD, FACS, Chairman, Department of Ophthalmology, University of Pittsburgh                                                                                                                       |
| 8:00 – 8:06 am | Welcome and Opening Remarks                                         | Adrienne Graves, PhD and Andrew G. Iwach, MD Co-Founders and Co-Chairs, Glaucoma 360                                                                                                                   |
| 8:06 – 8:32 am | Opening Keynote Address                                             | Drs. Henry and Frederick Sutro Memorial Lecture  
Paul P. Lee, MD, JD, “Opportunities and Challenges for Innovation in Glaucoma”  
Professor and Chair, Department of Ophthalmology, Director, W.K. Kellogg Eye Center, University of Michigan |
| 8:32 – 9:55 am | New Horizons in Glaucoma Drug Delivery                              | Moderators: Robert D. Fechtner, MD, Director, Glaucoma Division, Department of Ophthalmology and Visual Sciences, Rutgers New Jersey Medical School  
Eliot Lazar, MD, President, eCON Enterprises, Inc.  
Participants:  
- DSM Biomedical – Mirian Gillissen, Program Manager Drug Delivery  
- Envisia Therapeutics – Benjamin Yerxa, PhD, Chief Scientific Officer  
- Euclid Systems – Dale DeVore, PhD, Chief Scientific Officer  
- ForSight VISION5 – John Maroney, CEO  
- GrayBug – Michael O’Rourke, President and CEO  
- Mati Therapeutics – Bob Butchofsky, Founder and CEO  
- Ocular Therapeutix – Art Driscoll, Vice President of Product Development  
- Replenish – Sean Caffey, MD, Chairman, CEO, and Co-Founder  
Q&A                                                                 |
| 9:55 – 10:20 am | Break, Exhibits and Networking Opportunity                           |                                                                                                                                                                                                 |
| 10:20 – 10:40 am | Catalyst for a Cure Biomarkers Initiative                           | “Early Neuronal Changes: Markers for Glaucoma”  
Thomas M. Brunner, President and CEO, Glaucoma Research Foundation  
Andrew D. Huberman, PhD, Assistant Professor in the Department of Neurosciences, Division of Biological Sciences, Department of Ophthalmology, University of California, San Diego; Assistant Adjunct Professor, Salk Institute for Biological Studies |
| 10:40 – 11:40 am | New Horizons in IOP Monitoring, Diagnostics, and Digital Health      | Speaker/Moderator: Robert N. Weinreb, MD, Chairman and Distinguished Professor of Ophthalmology, Director of the Shiley Eye Center; Director of the Hamilton Glaucoma Center, University of California at San Diego  
Co-moderator: Rohit Varma, MD, MPH, Grace and Emery Beardsley Professor and Chair, Department of Ophthalmology; Director, USC Eye Institute; Associate Dean, Keck School of Medicine at USC  
Participants:  
- Implantdata Ophthalmic Products GmbH – Max Ostermeier, President and CEO  
- Sensimed—David Bailey, CEO  
- SOLX—Doug Adams, Founder and CEO  
- Wills Eye Hospital – George Spaeth, MD, Louis Esposito Research Professor of Ophthalmology  
- American Academy of Ophthalmology – David Parke, II, MD, Executive Vice President and CEO  
Q&A                                                                 |
| 11:40 – 12:08 pm | Funding New Horizons: Venture Capital Panel Discussion               | Moderators: Richard L. Lindstrom, MD, Founder, Minnesota Eye Consultants  
Alan S. Crandall, MD, Presidential Professor of Ophthalmology and Visual Services, Senior Vice Chair, Director of Glaucoma and Cataract, Co-Director, Division of International Ophthalmology, John A. Moran Eye Center  
Panelists:  
- Eugene de Juan, Jr., MD, Founder and Vice Chairman, ForSight Labs  
- Gil Kliman, MD, Managing Director, InterWest Partners  
- Ed Mathers, Partner, New Enterprise Associates  
- Philip Oettinger, Partner, Wilson Sonsini Goodrich & Rosati                                                                 |
| 12:08 – 1:08 pm | Luncheon                                                             | Afternoon Master of Ceremonies  
Ruth D. Williams, MD, President, Wheaton Eye Clinic                                                              |
### Program and Speakers

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Moderators</th>
<th>Participants</th>
<th>Panelists</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:10 – 1:35 pm</td>
<td><strong>New Horizons in Glaucoma Pharmaceuticals</strong></td>
<td>Paul Chaney, President and CEO, PanOptica, Inc.</td>
<td>Aerie Pharmaceuticals – Thomas Mitro, Vice President and COO</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Eydie Miller-Ellis, MD, Professor of Clinical Ophthalmology, Director, Glaucoma Services, Scheie Eye Institute</td>
<td>Bausch + Lomb – Baldo Scassellati Sforzolini, MD, PhD, MBA, Vice President, Eye Care</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>1:35 – 2:10 pm</td>
<td><strong>Industry Panel Discussion: Glaucoma Pharmaceuticals</strong></td>
<td>Gary D. Novack, PhD, President, PharmaLogic Development, Inc.; Visiting Professor of Pharmacology and Ophthalmology, University of California Davis, School of Medicine</td>
<td>Alcon Laboratories – Dough Hubatsch, Senior Brand Lead, Medical Affairs</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Kuldev Singh, MD, MPH, Professor of Ophthalmology, Director of Glaucoma Service, Standford University Medical Center</td>
<td>Allergan, Inc. – Michael R. Robinson, MD, Vice President of Clinical Development</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bausch + Lomb – Tracy M. Valorie, BS, MBA, Vice President, General Manager, Bausch + Lomb Pharmaceuticals</td>
<td></td>
</tr>
<tr>
<td>2:10 – 2:35 pm</td>
<td><strong>Break, Exhibits and Networking Opportunity</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:35 – 4:05 pm</td>
<td><strong>New Horizons in Glaucoma Devices</strong></td>
<td>Thomas W. Samuelson, MD, Founding Partner, Minnesota Eye Consultants; Adjunct Associate Professor of Ophthalmology, University of Minnesota</td>
<td>AqueSys – Ron Bache, President and CEO</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>EyeSonix, LLC – Don Schwartz, MD, OD, MPA, Founder and CEO</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>EyeTechCare – Dietrich Wolf, PhD, CEO</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Glaukos Corporation – Bruce Nogales, Chief Corporate Development Officer</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>InnFocus, Inc. – Russ Trenary, President and CEO</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>iSTAR Medical – Michel Vanbrabant, CEO</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Ivantis – Brett Trauthen, Chief Scientific Officer</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>New World Medical – Suhail Abdullah, Director of Research and Development</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Transcend Medical – Sean Ianchulev, MD, MPH, Chief Medical Officer</td>
<td></td>
</tr>
<tr>
<td>4:05 – 4:35 pm</td>
<td><strong>Industry Panel Discussion: Glaucoma Devices</strong></td>
<td>K. Angela MacFarlane, JD, President and CEO, ForSight Labs</td>
<td>Abbott Medical Optics, Inc. – Jane Rady, Division Vice President</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cynthia Mattox, MD, FACS, Director, Glaucoma and Cataract Service, New England Eye Center; Associate Professor and Vice Chair, Department of Ophthalmology, Tufts University School of Medicine</td>
<td>Alcon Laboratories, Inc. – Ernie Bravo, Global Marketing Director, Surgical Glaucoma</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bausch + Lomb – Tracy M. Valorie, BS, MBA, Vice President, General Manager, Bausch + Lomb Pharmaceuticals</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Carl Zeiss Meditec, Inc. – Ralf Kuschmireit, PhD, President and CEO</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Haag-Streit – Ernest Cavin, PhD, President</td>
<td></td>
</tr>
<tr>
<td>4:35 – 5:10 pm</td>
<td><strong>Getting to New Horizons: FDA Panel Discussion</strong></td>
<td>Wiley A. Chambers, MD, Supervisory Medical Officer, Division of Transplant &amp; Ophthalmology Products, FDA</td>
<td>Wiley A. Chambers, MD, Supervisory Medical Officer, Division of Transplant &amp; Ophthalmology Products, FDA</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Malvina B. Eydelman, MD, Division Director, Division of Ophthalmic Device Evaluation, FDA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:10 – 5:20 pm</td>
<td><strong>Forum Summation</strong></td>
<td>George A. Cioffi, MD, Edward S. Harkness Professor and Chairman, Columbia University College of Physicians and Surgeons; Ophthalmologist-in-Chief, New York-Presbyterian Hospital/Columbia University Medical Center</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:20 – 5:22 pm</td>
<td><strong>Closing Remarks</strong></td>
<td>Adrienne L. Graves, PhD and Andrew G. Iwach, MD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:30 – 6:30 pm</td>
<td><strong>Reception, Exhibits, and Networking</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Advisory Board

Stuart B. Abelson, MBA
President, Chief Executive Officer,
Ora, Inc.

Anthony P. Adamis, MD
Vice President, Global Head
of Ophthalmology,
Genentech, Inc.

Paul Chaney
President and Chief Executive Officer,
PanOptica, Inc.

George A. Cioffi, MD
Chairman, Department of Ophthalmology
Columbia University College
of Physicians and Surgeons

Alan S. Crandall, MD
Director of Glaucoma and Cataract,
Senior Vice Chairman of Ophthalmology &
Visual Sciences
John A. Moran Eye Center, University of Utah

Emmett Cunningham, Jr., MD,
PhD, MPH
Partner,
Clarus Ventures

Eugene de Juan, Jr., MD
Founder and Vice-Chairman,
ForSight Labs

John W. Grunden, PharmD
Regional Director of Medical Affairs,
Merck & Co., Inc.

David Guyer, MD
Partner,
SV Life Sciences Advisers, LLC

Eve Higginbotham, SM, MD
Vice Dean, Perelman School of Medicine,
University of Pennsylvania

H. Dunbar Hoskins, Jr., MD
Co-Founder and Director,
Glaucoma Research Foundation
Former Executive Vice President,
American Academy of Ophthalmology

Wende Hutton
General Partner,
Canaan Partners

Ralf Kuschnereit, PhD
President and Chief Executive Officer,
Carl Zeiss Meditec, Inc.

Eliot Lazar, MD
President,
eCON Medical

Paul Lee, MD, JD
F. Bruce Fralick Professor and Chair,
Department of Ophthalmology and Visual Sciences
Director, W.K. Kellogg Eye Center,
University of Michigan

Richard L. Lindstrom, MD
Founder,
Minnesota Eye Consultants, PA

William J. Link, PhD
Managing Director,
Versant Ventures

Sabri Markabi, MD
Senior Vice President,
Research and Development and
Chief Medical Officer,
Alcon Laboratories, Inc.
Advisory Board

James Mazzo
Operating Partner, Versant Ventures
Chairman and Chief Executive Officer, AcuFocus

J. Casey McGlynn, JD
Partner, Wilson Sonsini Goodrich & Rosati

Gary D. Novack, PhD
President, PharmaLogic Development, Inc.
Visiting Professor of Pharmacology and Ophthalmology, University of California Davis, School of Medicine

David E.I. Pyott
Chairman of the Board, President and Chief Executive Officer, Allergan, Inc.

Thomas W. Samuelson, MD
Founding Partner, Minnesota Eye Consultants
Adjunct Associate Professor of Ophthalmology, University of Minnesota

Murthy V. Simhambhatla, PhD
President, Abbott Medical Optics, Inc.
Senior Vice President, Abbott Laboratories

Kuldev Singh, MD, MPH
Professor of Ophthalmology and Director, Glaucoma Service
Stanford University Medical Center

Ellen StrahIman, MD, MHSc
Chief Medical Officer and Senior Vice President, Research and Development, Becton, Dickinson & Company

Daniel M. Wechsler
EVP and Company Group Chairman, Ophthalmology and Eye Health, Bausch + Lomb

Tracy M. Valorie, BS, MBA
Vice President, Pharmaceutical Marketing, Bausch + Lomb

Robert N. Weinreb, MD
Chairman & Director, Shiley Eye Center, Director, Hamilton Glaucoma Center, University of California, San Diego

Ruth D. Williams, MD
President, Wheaton Eye Clinic

M. Roy Wilson, MD, MS
President, Wayne State University

NEW HORIZONS FORUM
Sincere Thanks to Our Media and Strategic Partners

Bryn Mawr Communications
Elsewhere Advertising
International Business Forum
Ophthalmology Innovation Summit

Ophthalmology Times
Ophthalmic Women Leaders
Wilson Sonsini Goodrich & Rosati
THINKING OUTSIDE THE BOTTLE

Exploring the full potential of our offerings, researching new therapeutic options, and providing you with the resources you need to treat this condition. That’s how we’re helping you manage your glaucoma patients today and tomorrow.
<table>
<thead>
<tr>
<th>Name</th>
<th>Title and Affiliations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ike Ahmed, MD, FRCSC</td>
<td>Assistant Professor, Faculty of Medicine, University of Toronto, Clinical Assistant Professor, University of Utah</td>
</tr>
<tr>
<td>Lama A. Al-Aswad, MD</td>
<td>Associate Professor of Ophthalmology, Columbia University Medical Center</td>
</tr>
<tr>
<td>Anne L. Coleman, MD, PhD</td>
<td>Frances and Ray Stark Professor of Ophthalmology, Stein Eye Institute, David Geffen School of Medicine at UCLA, Professor of Epidemiology, Jonathan and Karin Fielding School of Public Health, University of California, Los Angeles</td>
</tr>
<tr>
<td>Robert Fechtner, MD</td>
<td>Professor, Institute of Ophthalmology and Visual Science, Director, Glaucoma Division, UMDNJ-New Jersey Medical School</td>
</tr>
<tr>
<td>Larry Haimovitch</td>
<td>Founder, Haimovitch Medical Technology Consultants</td>
</tr>
<tr>
<td>L. Jay Katz, MD</td>
<td>Director, Glaucoma Service, Wills Eye Hospital, Professor of Ophthalmology, Jefferson Medical College</td>
</tr>
<tr>
<td>Richard A. Lewis, MD</td>
<td>Grutzmacher, Lewis &amp; Sierra Surgical Eye Specialists, Former Director of Glaucoma, University of California, Davis</td>
</tr>
<tr>
<td>Shan Lin, MD</td>
<td>Professor of Clinical Ophthalmology, Director, Glaucoma Service, and Director, Glaucoma Fellowship Program, Department of Ophthalmology, University of California, San Francisco</td>
</tr>
<tr>
<td>Eydie G. Miller-Ellis, MD</td>
<td>Professor of Clinical Ophthalmology, Scheie Eye Institute, University of Pennsylvania</td>
</tr>
<tr>
<td>Mildred M.G. Olivier, MD</td>
<td>Associate Clinical Professor, Rosalind Franklin University of Medicine and Science, Associate Clinical Professor, Midwestern University, Chief Executive Officer and Founder, Midwest Glaucoma Center, P.C.</td>
</tr>
<tr>
<td>Joel S. Schuman, MD, FACS</td>
<td>Eye &amp; Ear Foundation Professor, Chairman, Department of Ophthalmology, Professor of Bioengineering, University of Pittsburgh</td>
</tr>
<tr>
<td>Robert Stamper, MD</td>
<td>Professor of Clinical Ophthalmology, Director, Glaucoma Service, University of California, San Francisco</td>
</tr>
<tr>
<td>James C. Tsai, MD, MBA, FACS</td>
<td>Robert R. Young Professor of Ophthalmology and Visual Science, Chair, Department of Ophthalmology &amp; Visual Science, Yale School of Medicine</td>
</tr>
<tr>
<td>Steven Vold, MD</td>
<td>Founder and Chief Executive Officer, Vold Vision, Chief Medical Editor, Glaucoma Today</td>
</tr>
<tr>
<td>Barbara Wirostko, MD</td>
<td>Clinical Adjunct Associate Professor, Moran Eye Center, University of Utah</td>
</tr>
</tbody>
</table>
Adrienne Graves, PhD
Independent Director:
Aerpio Therapeutics; Akorn, Inc.; Encore Vision, Inc.;
Envisia Therapeutics, Nicox S.A.; Tearlab Corporation
Co-Founder and Co-Chair, Glaucoma 360
Board of Directors,
Glaucoma Research Foundation

Dr. Graves is a visual scientist and a global industry leader in ophthalmology. She was President and CEO of Santen Inc., the US arm of Japan’s largest ophthalmic pharmaceutical company. Earlier, Dr. Graves spent nine years with Alcon Laboratories in various Research & Development roles including Director of International Ophthalmology. Dr. Graves currently serves as an Independent Director on the boards of Aerpio Therapeutics; Akorn, Inc., Encore Vision, Inc.; Envisia Therapeutics, Nicox S.A.; and Tearlab Corporation.

She is also a Board Director for foundations including American Society of Cataract and Refractive Surgery (ASCRS) Foundation, American Academy of Ophthalmology (AAO) Foundation (Emeritus), KeepYourSight, and Himalayan Cataract Project. She also serves on the Corporation Committee for the Brown University Medical School.

Dr. Graves received the 2015 Catalyst Award from Glaucoma Research Foundation for her dedication and leadership on the Board in sustaining innovative glaucoma research.

Dr. Graves did her undergraduate studies at Brown University, her PhD work at the University of Michigan, and a postdoctoral fellowship in visual neuroscience at the University of Paris.

Andrew G. Iwach, MD
Executive Director, Glaucoma Center of San Francisco and Executive Director, Glaucoma Research and Education Group, Co-Founder and Co-Chair, Glaucoma 360, Board of Directors, Glaucoma Research Foundation

Dr. Iwach has been a member on the Board of Directors for the Glaucoma Research Foundation since 2000 and is currently serving as its Chair. He is Co-Founder of the Eye Surgery Center of San Francisco.

He currently serves as a scientific reviewer for many top professional publications, and in 2004 he received the Academy’s Senior Achievement Award and in 2012 the Academy’s Secretariat Award.

Dr. Iwach is an Associate Clinical Professor of Ophthalmology in the Department of Ophthalmology at the University of California San Francisco.

He is on the clinical faculty at California Pacific Medical Center. He teaches courses and lectures extensively on glaucoma. Dr. Iwach is actively involved in clinical research, as well and his focus has included mitomycin-C use in filtering surgery, application of optical coherence tomography in glaucoma, selective laser trabeculoplasty, numerous drug trials and more.

He has published more than 40 peer-reviewed papers and book chapters.

H. Dunbar Hoskins, Jr., MD
Former Executive Vice President, American Academy of Ophthalmology
Co-Founder, Glaucoma Research Foundation Steering Committee, Glaucoma 360

Dr. Hoskins is an internationally recognized glaucoma specialist and was the Executive Vice President of the American Academy of Ophthalmology from January 1, 1993 to March 31, 2009. He received an Academy Honor Award in 1979, a Senior Honor Award in 1989, and Distinguished Service Award in 1999.

He has held numerous positions in ophthalmology, medicine and business including: Founding Director of the American Glaucoma Society, founder and Director of the Foundation for Glaucoma Research, Secretary-Treasurer of the Pan American Association of Ophthalmology, and Chairman of the Advisory Committee to the International Council of Ophthalmology.

He is a Clinical Professor of Ophthalmology at the University of California School of Medicine, San Francisco, where he did his Glaucoma Fellowship.

Dr. Hoskins received his medical degree at the Medical College of Virginia. He was certified by the American Board of Ophthalmology in 1970. He served as Chief of Ophthalmology at the Naval Hospital in Rhode Island in 1968.

Thomas M. Brunner
President and Chief Executive Officer, Glaucoma Research Foundation
Steering Committee, Glaucoma 360

Mr. Brunner joined Glaucoma Research Foundation in 2003 after a successful 30-year career in the ophthalmic laser business. He helped introduce major advances in eye care including laser photocoagulation to prevent vision loss from diabetic retinopathy, laser treatment of secondary cataracts, and laser treatment for glaucoma.

Since joining Glaucoma Research Foundation, Tom has helped to more than double revenue and focus on innovative research to understand how glaucoma steals sight and find a cure. He received a “Lifetime Achievement” award from the American Society for Laser Medicine and Surgery for his contributions and 25 years of service on their Board of Directors.

Tom actively supports development of new products to help those with glaucoma and other eye diseases as an advisor or board member for startup companies in the eye care field. Tom graduated from Lehigh University with a degree in electrical engineering and received an MBA from the University of Delaware.
Leadership

L. Jay Katz, MD
Director, Glaucoma Service,
Wills Eye Hospital
Professor of Ophthalmology,
Jefferson Medical College

Dr. Katz has wide-ranging interests in glaucoma, including drug evaluation, laser and medical management in glaucoma treatment, optic nerve scanning methodologies, and glaucoma surgical techniques.

He is on the advisory boards of pharmaceutical and glaucoma device companies, including Glaukos, Bausch + Lomb, Allergan, Aerie, and Merck.

Dr. Katz received his BA from Case Western Reserve University and his MD from Yale University School of Medicine. He completed his ophthalmology residency at Yale and then moved to Wills Eye Hospital for his glaucoma subspecialty training.

Ruth D. Williams, MD
President,
Wheaton Eye Clinic

Dr. Williams is CEO of the Wheaton Eye Clinic, a 73-year-old ophthalmology practice that provides subspecialty eye care to more than 140,000 patients annually.

She is a past president of the American Academy of Ophthalmology, representing ophthalmology at the AMA for nearly a decade and chairing its specialty section.

After attending Rush Medical College, Dr. Williams completed an ophthalmology residency at California Pacific Medical Center in San Francisco and a glaucoma fellowship at Shaffer Associates and the University of California San Francisco.

Opening Keynote Address
Drs. Henry and Frederick Sutro Memorial Lecture

Paul P. Lee, MD, JD
F. Bruce Fralick Professor and Chair of Ophthalmology and Visual Sciences
Director, W.K. Kellogg Eye Center
University of Michigan

Paul P. Lee, MD, JD, is the F. Bruce Fralick Professor and Chair of the Department of Ophthalmology and Visual Sciences at the University of Michigan, and Director of the W.K. Kellogg Eye Center.

He has published over 200 papers on glaucoma and eye care delivery, particularly on understanding and improving eye care. His research interests include improving access to and the quality of health care, patient-centered care and exploring the impact of health policy and financing on patients and populations.

Dr. Lee also serves as consultant to the Centers for Disease Control and Prevention, on the Board of Directors of the American Board of Ophthalmology, on the Advisory Committee of the Hoskins Center for Patient Safety and Quality of the American Academy of Ophthalmology Foundation, and member of the Board of Governors and Chair of the Foundation of the Association of Research in Vision and Ophthalmology.
Mirian Gillissen is Program Manager for Drug Delivery at DSM Biomedical. She is responsible for the development of the glaucoma product utilizing DSM’s material portfolio. Mirian has worked for many years in the medical device industry in the field of natural biopolymers and sustained drug delivery applications before joining DSM Biomedical.

Dr. Yerxa is a co-founder of Envisia Therapeutics, an ophthalmic drug delivery company spun out of Liquidia Technologies. Previously, he was Vice President of Research and Development at Clearside Biomedical and the Executive Vice President and Chief of Research & Development at Inspire Pharmaceuticals, a top-ranked publicly-traded biotech company acquired by Merck & Co., Inc. During his time at Inspire, Dr. Yerxa helped the company build and commercialize a portfolio of innovative new products.

Throughout his 20-year career in the pharmaceutical and biotechnology industry, Dr. Yerxa has been involved with the discovery and development of several investigational new drugs (INDs), phase 3 clinical programs, new drug applications (NDAs), and drug approvals.

His experience spans a variety of therapeutic areas including ophthalmology, pulmonary, cardiovascular, and HIV.

Dr. DeVore received his PhD from Rutgers University, has worked for Battelle Memorial Institute, 3M, and several medical device companies and is a well-known independent consultant to the medical device and tissue engineering industry.

He is considered one of the experts in the development and application of collagen compositions for ophthalmology, dermatology and orthopedics and is inventor or co-inventor on more than 75 issued and pending patents and has authored/co-authored more than 60 articles in the field.

Mr. O’Rourke has 19 years of global ophthalmic leadership, strategy, and commercialization experience across pharmaceuticals, drug delivery, and medical devices.

He was appointed President and CEO of GrayBug in October 2013 after serving as a member of the GrayBug Scientific Advisory Board. Prior to GrayBug he founded Scotia Vision Consultants, specializing in strategic planning for start-up ophthalmic companies in the USA and Europe. He was General Manager for the Bausch + Lomb U.S. Pharmaceuticals division (2004-2009) and held senior global strategy positions in their pharmaceuticals and surgical divisions.

Additional experience includes Chiron Vision Europe (ophthalmics), Alza International (drug delivery), Pfizer Hospital Products (Howmedica, Orthopedics) in Europe and Asia and 3M Pharmaceuticals in the UK.

Robert Butchofsky is the Founder and CEO of Mati Therapeutics. Headquartered in Austin, Texas, Mati is developing a non-invasive...
sustained drug delivery platform to treat ocular diseases, in particular glaucoma. Mr. Butchofsky is the former President and CEO of QLT Inc., a publicly traded Vancouver-based biotech company focused on ocular diseases and the company responsible for the first medical treatment for age related macular degeneration, Visudyne®. From June 1990 to August 1998, Mr. Butchofsky was employed at Allergan Inc. where he built an extensive background with ocular pharmaceutical products and Botox, including sales, health economics, worldwide medical marketing, and product management. Mr. Butchofsky has over 20 years of commercial and development experience in ophthalmology.

Art Driscoll
Vice President of Product Development
Ocular Therapeutix

Art has more than 20 years of biomaterials, medical device and biotech experience in both public and private companies, with a strong record of developing technologies from bench top through commercialization. Prior to joining Ocular Therapeutix in 2011, Mr. Driscoll was Vice President of BioSurgery R&D for Covidien’s Surgical Solutions business and previously held senior management positions at Confluent Surgical and Boston Scientific. Mr. Driscoll has a BS degree in industrial technology and was a candidate for an MS degree in plastics engineering from the University of Lowell.

Max G. Ostermeier, MBA
Chief Executive Officer and President
Implandata Ophthalmic Products GmbH

Max G. Ostermeier (MBA) is founder and CEO of Implantdata Ophthalmic Products GmbH, Hannover/Germany and CEO and President of its US based affiliate, Implantdata Ophthalmic Products, Inc., Wilmington/DE. Max has extensive experience in the commercial development of technologically advanced products and in building operational capabilities for aggressively growing companies.

As a serial entrepreneur he was founder and CEO of several medical device start-up companies in Germany and the US and instrumental to proceed these companies to a successful exit. For close to 15 years now, Max is involved in the development of ophthalmic surgical products, working with leading institutes and researches in order to address currently unmet medical needs in eye care.

David Bailey
Chief Executive Officer
Sensimed

David started his career with Johnson and Johnson progressing through numerous roles before becoming Ophthalmic Franchise Director for Europe in 1993. Following the sale to Chiron Vision he took charge of the combined business to create a highly profitable franchise. This facilitated the acquisition by Bausch and Lomb, where he became Surgical Business Head for Europe and Asia. In 2001 David became Chairman and CEO of STAAR Surgical where he successfully transitioned the business to a cutting edge refractive franchise. He joined Sensimed in the autumn of 2014 and continues to operate at Board level with two other companies.

Doug Adams
Founder and Chief Executive Officer
SOLX

Doug Adams became CEO of SOLX on December 19, 2007 with the acquisition of SOLX from OccuLogix, a company he originally founded in 2000.

Mr. Adams has an accomplished history in the ophthalmic industry with more than 30 years of experience as an operating executive and entrepreneur.
From the first engineering sketch through to quality testing and production, every part of the Tango™ SLT/YAG combination laser is designed and manufactured by Ellex.

Featuring a proprietary, patented dual-mode laser cavity, combined with a custom-built power supply, Tango™ allows you to perform SLT and YAG treatments with improved accuracy and greater efficacy over the long-term.

Simply put, Tango™ is the industry’s leading SLT/YAG laser.

Visit www.ellex.com/us/Built-by-Ellex or call 855.767-5784 to learn more.
Over a Decade of Excellence in Glaucoma Treatment

We wholeheartedly endorse the GRF mission “to prevent vision loss from glaucoma by investing in innovative research, education, and support with the ultimate goal of finding a cure.”

We’re proud to offer the most researched SLT laser therapy in the world used by many of the best ophthalmologists in the world.

Lumenis supports the Glaucoma Research Foundation.

Here’s how we care for glaucoma patients:

• Proven clinical outcomes
• Trusted technology
• Effective first line therapy

To learn more about Lumenis SLT, visit ophthalmic.lumenis.com/slt.

Presenting Companies

He has founded six companies in the ophthalmic industry focusing primarily on implantable devices for glaucoma. He has served on industry advisory boards for a number of universities.

He holds a BBA from the University of Georgia and has completed executive leadership courses from Columbia University, and Wharton School of Business.

George L. Spaeth, MD
Louis Esposito Research Professor of Ophthalmology
Wills Eye Hospital/Jefferson Medical College

George L. Spaeth, MD was Director of the William and Anna Goldberg Glaucoma Service and Research Laboratories at the Wills Eye Institute/Jefferson Medical College from 1968 to 2007, where he is now the Louis J. Esposito Research Professor and Director of Medical Research & Education of the Glaucoma Service at Wills Eye Hospital.

He has published over 360 articles in peer-reviewed journals. His surgical text is used in many countries around the world and a fourth edition has just been published.

He serves on the editorial boards of six journals, and was for many years Editor in Chief of Ophthalmic Surgery. Dr. Spaeth is the founding member and first President of the American Glaucoma Society.

Dr. Parke is Executive Vice President and CEO of the American Academy of Ophthalmology. A graduate of Stanford University and Baylor College of Medicine, Dr. Parke completed residency training and chief residency at Baylor followed by two years of fellowship in retina and vitreous at Baylor and at the Medical College of Wisconsin.

Prior to assuming his Academy position, Dr. Parke served as president and CEO of the Dean McGee Eye Institute and Edward L. Gaylord Professor and Chair of the Department of Ophthalmology in the University of Oklahoma College of Medicine.

Dr. Parke was elected and served as president of the American Academy of Ophthalmology in 2008. Other positions include director of the Ophthalmic Mutual Insurance Company (OMIC) and the Council of Medical Specialty Societies.

What we do every day matters.

Avenova™ with Neutrox™ (pure hypochlorous acid) removes microorganisms and debris from the lids and lashes. Avenova is an ideal addition to any daily lid and lash hygiene regimen, including for use by patients with Blepharitis and Dry Eye. Avenova may also be used after make-up removal as well as pre and post contact lens wear.

What we do every day matters.
Presenting Companies

New Horizons in Glaucoma Pharmaceuticals

Thomas Mitro
President and COO
Aerie Pharmaceuticals, Inc.

Mr. Mitro has over 30 years of pharmaceutical industry experience in sales and marketing, commercial operations, and business development. Prior to joining Aerie, he most recently served as Vice President, Sales and Marketing at Omeros Corporation, a publicly traded clinical-stage biopharmaceutical company.

Before this, he was Vice President, Sales and Marketing at ISTA Pharmaceuticals, where he was instrumental in building commercial operations and launching several eye care products. At the time of ISTA’s acquisition by Bausch + Lomb, ISTA had grown to become the third largest branded prescription eye care business in the U.S.

Previously, he held various positions at Allergan, Inc., including Vice President, Skin Care; Vice President, Business Development; and Vice President, e-Business.

He received his BS degree from Miami University.

Baldo Scassellati Sforzolini, MD, PhD, MBA
Vice President
Eye Care
Bausch + Lomb

Baldo Scassellati Sforzolini is Vice President Development Eye Care at Valeant Pharmaceuticals.

Prior to Valeant he was Vice President Global Development at Bausch + Lomb and Vice President Ophthalmology Development at Novartis, and held positions of increased responsibilities at Pfizer and Pharmacia.

Dr. Scassellati Sforzolini holds an MD from the University of Bologna, a PhD in Neurosensory Science and Ophthalmology Residency from the University of Ancona, a diploma of Pharmaceutical Medicine from Cardiff University and an MBA from Cranfield School of Management.

New Horizons in Glaucoma Devices

Ron Bache
President and Chief Executive Officer
AqueSys Inc.

Ron Bache is President and CEO of AqueSys, Inc. AqueSys is a venture capital backed medical device company focused on the development, and commercialization of innovative, minimally invasive, and highly effective implantable devices for the treatment of glaucoma. Bache has over 20 years of experience in the pharmaceutical and medical device industry.

Ron has led multiple market changing technologies, and has held leadership roles for high growth global businesses generating hundreds of millions of dollars annually.

Bache earned his Bachelor of Science in Business Administration with an emphasis in Finance and Entrepreneurship from the University of Southern California, where he also played rugby. Ron further completed executive education programs at Stanford Business School and Harvard Business School.

Donald Schwartz, MD, OD, MPA
Founder and President
EyeSonix

Dr. Schwartz has been in private clinical practice for over 30 years and is an Associate Clinical Professor at the USC department of Ophthalmology. He has held both Statewide and National positions as President of the California Academy of Ophthalmology, and served on the Boards of both the American Academy and American Board of Ophthalmology. He has also served as Chair of the Board of MES, a national vision care plan.

EyeSonix is a Medical device company which has developed a low power, low frequency ultrasound treatment for open-angle glaucoma. The device is portable and does not require a slit lamp or biomicroscope.

Dietrich Wolf, PhD
Chief Executive Officer
EyeTechCare

Dietrich Wolf is CEO of EyeTechCare, a French ophthalmic device company. Innovation and disruptive medical technologies providing a significant patient benefit are his passion. Through his career at Carl Zeiss Meditec (Germany) and Dentsply International (USA) he pioneered and marketed new technologies in cancer care and dental devices all of which became new standards of care. He won prestigious innovation and start-up awards in the USA and Europe.

Dietrich Wolf holds a PhD in Materials Science from the University of Erlangen, Germany. He did executive education programs at Harvard Business School, Boston, MA, at UNC Keenan-Flagler Business School in Chapel Hill, NC and St. Gallen Business School in Switzerland.
Presenting Companies

Bruce Nogales  
Chief Corporate Development Officer,  
Glaukos Corporation

Bruce Nogales has over 28 years of Life Science business experience. Bruce is the Chief Corporate Development Officer at Glaukos Corporation.

Prior to joining Glaukos, Bruce was Sr. Vice President and General Manager at Talecris Biotherapeutics where he was responsible for all business activities outside the U.S. and the vertical integration and management of all plasma supply activities within the U.S.

He began his Life Science career with Allergan Pharmaceuticals and Allergan Medical Optics where he held numerous sales and marketing positions.

Bruce received a BS degree in Finance from California State University, Long Beach and completed the Executive Development Program at the University of Pennsylvania’s Wharton School of Business. He resides in Raleigh, North Carolina with his wife and three daughters.

Russ Trenary  
President and Chief Executive Officer,  
InnFocus, Inc

Russ Trenary is President & CEO for InnFocus, Inc., an early stage company pioneering microsurgical solutions for glaucoma. He has led, or been a named officer, for medical device companies, for over 20 years.

His managerial experience includes specific interfacing in Marketing / Sales / Finance / R&D / Clinical / Regulatory / Manufacturing. He has turned unprofitable $100MM divisions at Allergan (NYSE:AGN) into highly profitable entities, and also significantly increased profitability in $500MM divisions at AMO (NYSE:EYE). He also has vast experience with large volume product launch and acquisitions like Pharmacia Surgical, Ioptex, VISX, Intralase, and Optical Micro Systems.

---

TIMOPTIC® in OCUDOSE®  
(TIMOLOL MALEATE 0.5% \( \text{OPHTHALMIC SOLUTION) \})

Istalol®  
(timolol maleate ophthalmic solution) 0.5%

Timoptic and OcuDose are trademarks of Valeant Pharmaceuticals International, Inc. or its affiliates.

ISTALOL is a registered trademark of Bausch & Lomb Incorporated or its affiliates.

© 2014 Bausch & Lomb Incorporated.  US/TOP/14/0019  10/14

BAUSCH + LOMB
Presenting Companies

**Michel Vanbrabant**
Chief Executive Officer
iSTAR Medical

iSTAR Medical is a venture-backed company aiming to improve the lives of patients suffering from eye diseases by developing innovative ophthalmic implants.

Mr. Vanbrabant is an entrepreneurial healthcare executive with 20 years of experience in General Management, Sales & Marketing, Clinical and Reimbursement. Prior to joining iSTAR he held several international positions at leading MedTech companies including Guidant Inc. (now Boston Scientific) and St. Jude Medical Inc. in Cardiology, Neurology and Respiratory fields. Since 2011 he focused on new ventures, introducing innovative medical technologies to market, driving therapy adoption and value growth.

Michel Vanbrabant holds a Business Engineer degree from the Solvay School of Economics and Management, Brussels, Belgium and an executive MBA from Columbia University, New York.

**Sean Ianchulev, MD, MPH**
Chief Medical Officer and VP of Business Development, Transcend Medical
Venture Partner, Tullis Health Investors
Clinical Associate Professor of Ophthalmology, UCSF

Dr. Ianchulev is physician-scientist, developer and innovator. Over the past 15 years he has been involved in the development of key technologies in ophthalmology, including Lucentis while at Genentech.

He is also the founder of intraoperative aberrometry for cataract surgery and pioneered technology for high precision cataract surgery.

Dr. Ianchulev is an Associate Clinical Professor at UCSF and has authored work cited by over 2,000 of peer-reviewed publications in the field. He is also a partner at Tullis Health Investors—a private equity firm for life-science investments.

Dr. Ianchulev received his MD and a master’s of public health from Harvard University and completed specialty training at the Doheny Eye Institute, University of Southern California.

**Suhail Abdullah**
Director of Research and Development
New World Medical

New World Medical (NWM) manufactures and markets the Ahmed Glaucoma Valve. For over twenty years the company has been a leader in glaucoma drainage devices.

In his current position, Suhail Abdullah is helping the company develop and market new innovative ophthalmic products. Throughout his career at NWM, he has been involved in strategic planning, business development, device design, manufacturing, 510(k) submissions, and marketing. Suhail works with leading ophthalmologists to commercialize new ideas.

Mr. Abdullah earned a Bachelor’s in Cybernetics from the University of California Los Angeles and a Master’s in Bioscience from the Keck Graduate Institute of Applied Life Sciences.

**Brett Trauthen**
Chief Scientific Officer
Ivantis Inc.

Mr. Trauthen is the Chief Scientific Officer of Ivantis, responsible for clinical and pre-clinical research programs. Ivantis has over 500 patients currently enrolled in 6 clinical trials, and expects to double that number within the next 2 years. Mr. Trauthen has 20 years of experience in Research and Clinical management in multiple healthcare ventures. Prior to joining Ivantis in 2010, he held management positions at Devax Inc., Conor Medsystems, Radiance Medical Systems, and Applied Medical Resources, and Edwards Lifesciences.

Mr. Trauthen received a BS degree in Bioengineering from the University of California, Berkeley and an MS degree in Electrical Engineering from the University of California, Irvine. He is a coauthor of several publications and is an inventor or co-inventor on over 12 United States patents and patents pending.

**Sean Ianchulev, MD, MPH**
Chief Medical Officer and VP of Business Development, Transcend Medical
Venture Partner, Tullis Health Investors
Clinical Associate Professor of Ophthalmology, UCSF

Dr. Ianchulev is physician-scientist, developer and innovator. Over the past 15 years he has been involved in the development of key technologies in ophthalmology, including Lucentis while at Genentech.

He is also the founder of intraoperative aberrometry for cataract surgery and pioneered technology for high precision cataract surgery.

Dr. Ianchulev is an Associate Clinical Professor at UCSF and has authored work cited by over 2,000 of peer-reviewed publications in the field. He is also a partner at Tullis Health Investors—a private equity firm for life-science investments.

Dr. Ianchulev received his MD and a master’s of public health from Harvard University and completed specialty training at the Doheny Eye Institute, University of Southern California.
Stuart B. Abelson, MBA
President and Chief Executive Officer,
Ora, Inc.

Mr. Abelson has been a Director at Ora—a leading independent ophthalmic drug and device development firm—since 1995 and has served as the company’s Chairman from 1997 until his appointment as President in 2007.

Prior to joining Ora, Mr. Abelson served in various positions, including most recently Director of Technical Business Development at Amphenol, one of the largest manufacturers of interconnect products in the world. From 1999 through 2005, he served as General Manager of Amphenol’s fiber optic product division.

Mr. Abelson graduated Phi Beta Kappa and Magna Cum Laude with a BS degree in neuroscience from Bates College where he was a Charles A. Dana Scholar. He holds an MBA from Northwestern University’s Kellogg School of Management.

Ernie Bravo
Global Marketing Director, Surgical Glaucoma
Alcon Laboratories, Inc.

Ernie Bravo is a veteran of the Ophthalmic Industry as he has spent 20 plus years working with Alcon and other leading ophthalmic companies.

He has held increasing job responsibilities at Alcon that include roles in Surgical Cataract and Refractive. Most recently he was involved in the acquisition and merger of WaveLight GmbH which has grown to become the Industry leader in global excimer laser placements.

He was one of the founding sub-committee members of the Refractive Industry Council that support the advancement of laser refractive surgery. In his current role he is responsible for helping build Alcon’s Surgical Glaucma portfolio.

Thomas M. Brunner
President and Chief Executive Officer
Glaucoma Research Foundation

Mr. Brunner joined Glaucoma Research Foundation in 2003 after a successful 30-year career in the ophthalmic laser business. He helped introduce major advances in eye care including laser photoocoagulation to prevent vision loss from diabetic retinopathy, laser treatment of secondary cataracts, and laser treatment for glaucoma.

Since joining Glaucoma Research Foundation, Tom has helped to more than double revenue and focus on innovative research to understand how glaucoma steals sight and find a cure. He received a “Lifetime Achievement” award from the American Society for Laser Medicine and Surgery for his contributions and 25 years of service on their Board of Directors.

Ernest Cavin, PhD
President
Haag-Streit USA

Ernest Cavin, PhD is the President and CEO of Haag-Streit USA and Reliance Medical Products, Inc. in Mason, Ohio. These subsidiaries are part of Haag-Streit AG, located in Koeniz, Switzerland, an international corporation that manufactures some of the world’s most innovative and sophisticated medical equipment.

Cavin started his professional career in the watch industry with the Swatch Group, and then moved into the telecommunication field where he worked for 17 years. He has held leadership positions at Swiscom, Ascom, Lucent Technologies and Ciena, obtaining broad business experience and international expertise. In 2012, he joined the Haag-Streit USA.

Wiley A. Chambers, MD
Supervisory Medical Officer
Division of Transplant & Ophthalmology Products, FDA

Dr. Chambers is a Clinical Professor of Ophthalmology and Adjunct Assistant Professor of Computer Medicine at The George Washington University.

He joined the FDA in 1987, as a primary reviewer for ophthalmic drug products. In 1990 became a Supervisory Medical Officer for Ophthalmologic Drug Products. In this capacity, Dr. Chambers has supervisory responsibility for the clinical review of ophthalmologic drug products and ophthalmic therapeutic biologic products submitted to the FDA for study and potential approval. Dr. Chambers is the recipient of many awards for his work with the FDA.

With an undergraduate degree from Colgate University, Dr. Chambers completed medical school and a residency in Ophthalmology at The George Washington University School of Medicine and Health Sciences in Washington, DC.

Paul Chaney
President & Chief Executive Officer
PanOptica, Inc.

Paul G. Chaney is co-founder, President & CEO of PanOptica, Inc, a biopharma company developing PAN-90806, a novel topical anti-VEGF treatment for neovascular eye diseases.

Prior to founding PanOptica, Paul was EVP & President of (OSI) Eyetech. At Eyetech, Paul served as Chief Operating Officer and was responsible for the launch of Macugen, the first anti-VEGF treatment for neovascular age-related macular degeneration (wet-AMD).
Speakers, Moderators and Panelists

Paul has over 30 years of experience in the pharmaceutical industry, including a variety of senior management positions at Pharmacia Corporation where he launched Xalatan (latanoprost) and Xalcom (latanoprost/timolol) leading treatments for glaucoma.

Alan S. Crandall, MD
Presidential Professor of Ophthalmology and Visual Services, Senior Vice Chair, Director of Glaucoma and Cataract
Co-Director, Division of International Ophthalmology, John A. Moran Eye Center University of Utah

Dr. Crandall is a member of the American Society of Cataract and Refractive Surgery, American Glaucoma Society, the European Society of Cataract and Refractive Surgeons, as well as the International Intra-Ocular Implant Club.

He graduated from the University of Utah, receiving his medical degree from the University of Utah School of Medicine. Dr. Crandall completed his internship in surgery at the University of Pennsylvania Medical Center as well as his residency and fellowship in ophthalmology at the Scheie Eye Institute, University of Pennsylvania. He joined the University of Utah Ophthalmology Department in 1981.

Eugene de Juan, Jr., MD
Founder and Vice-Chairman, ForSight Labs

Dr. de Juan serves as Vice-Chairman of ForSight Labs and is the Jean Kelly Stock Distinguished Professor in Ophthalmology at UCSF. He’s participated in the development of a number of new technologies with over 100 products including the “retina chip,” minimally invasive retinal surgery, ocular drug delivery and the founding of nine venture-funded companies.

He’s previously served as Professor of Ophthalmology at the University of Southern California and Chief Executive Officer at the Doheny Retina Institute, Co-Director of Vitreoretinal Service at the Wilmer Eye Institute at Johns Hopkins University School of Medicine, Director of the Microsurgery Advanced Design Laboratory, and Joseph E. Green Professor of Ophthalmology.

He completed his medical degree and internship training at the University of South Alabama College of Medicine.

George A. Cioffi, MD
Edward S. Harkness Professor and Chairman, Columbia University College of Physicians and Surgeons
Ophthalmologist-in-Chief, New York-Presbyterian Hospital/Columbia University Medical Center

Dr. Cioffi is the Edward S. Harkness Professor and Chairman at Columbia University, Department of Ophthalmology. He also holds the Jean and Richard Deems Endowed Professorship and is the Ophthalmologist-in-Chief at New York Presbyterian Hospital. In 2014, he was elected as President of the Columbia Doctors Faculty Practice Organization and was appointed Vice Dean for Clinical Affairs.

Dr. Cioffi, a physician for 25 years, has published over 200 articles, has enjoyed support from the National Eye Institute of the National Institutes of Health for more than 18 years and has received many awards throughout his career. He has mentored more than 30 clinical and post-doctoral fellows that are now at academic institutions and in practices around world.

Malvina B. Eydelman, MD
Director, Division of Ophthalmic and Ear, Nose, and Throat Devices, ODE/CDRH/FDA

Dr. Eydelman is a board-certified ophthalmologist. She received her undergraduate degree in Electrical Engineering from Cooper Union for the Advancement of Science and Art. She received her MD degree from Harvard Medical School and a Doctorate in Health Sciences and Technology from Massachusetts Institute of Technology.

In 1995, Dr. Eydelman joined FDA. For the past 19 years, as an Expert Medical Officer, Senior Medical Advisor, Director of FDA’s Division of Ophthalmic, Neurological and Ear, Nose and Throat Devices and Director of the FDA’s Division of Ophthalmic and Ear, Nose and Throat Devices, she has played a key role in assuring the safety and effectiveness of ophthalmic medical devices.

She has been involved in standardization of ophthalmic devices as the U.S. Expert Delegate to the International Standards Organization and FDA’s Liaison to the American National Standards Institute’s Committee for Ophthalmic Devices.

Robert D. Fechtner, MD
Professor, Institute of Ophthalmology and Visual Science
Director, Glaucoma Division
Rutgers New Jersey Medical School

Robert D. Fechtner, MD, chairs the Institutional Review Board for human subject research at the New Jersey Medical School in Newark. He is also the Executive Vice President of the World Glaucoma Association.

Doug Hubatsch is the Senior Global Brand Leader, Medical Affairs for Alcon, and is responsible for the global pharmaceutical and surgical glaucoma portfolio. He began serving in this capacity in August 2010.

Prior to joining Alcon, Doug held various Medical Affairs roles at Hoffmann-La Roche and AstraZeneca subsequent to joining the pharmaceutical industry in 1997.

Doug holds a MSc from the University of Ottawa in Molecular Physiology and a HBSc in Biochemistry and Biotechnology from Carleton University.

Andrew D. Huberman, PhD
Assistant Professor in the Department of Neurosciences, Division of Biological Sciences, Department of Ophthalmology
University of California, San Diego

Dr. Huberman received his Ph.D. in Neuroscience in 2004 from UC Davis. From 2005-2010 he was a Helen Hay Whitney Postdoctoral Fellow in the laboratory of Dr. Ben Barres in the Department of Neurobiology at Stanford University School of Medicine. In 2011, Dr. Huberman joined the faculty of the UC San Diego as an Assistant Professor in the Departments of Neuroscience, Biology and Ophthalmology and he holds an adjunct professorship at the Salk Institute for Biological Studies.

Dr. Huberman is a McKnight Foundation Neuroscience Scholar, a Biomedical Scholar of the Pew Charitable Trust and Glaucoma Research Foundation Catalyst for a Cure team member.

Gil Kliman, MD
Managing Director
InterWest Partners

Dr. Kliman joined InterWest’s healthcare team in 1996, investing in a broad array of healthcare opportunities with a special interest in ophthalmology and medical devices including Autonomic Technologies, Benvenue Medical, Epocrates (EPOC), Glaukos, Gobiquity, IntraLase (ILSE), LenSx Lasers, Neuronetics, NeuroPace, On Demand Therapeutics, Restoration Robotics, and ReVision Optics.

Dr. Kliman has a BA from Harvard University. He received an MD from the University of Pennsylvania and an MBA from Stanford University. He completed ophthalmology residency at Wills Eye Hospital and a retina laser fellowship at Massachusetts Eye and Ear Infirmary.
ForSight Labs is a company focused on creating a community where innovation and practical application of ideas are combined to create companies focused on improving the lives of visually impaired patients. Since 2005, ForSight has started five companies focused on key needs in ophthalmology such as treatment of glaucoma and macular degeneration.

Prior to joining ForSight Labs, Ms. Macfarlane served as Chief Technology Counsel to The Foundry and as Technology Counsel for Thomas J. Fogarty, MD, where she participated in all aspects of early stage technology review, licensing, intellectual property management and company creation.

Ms. MacFarlane received her BA in Business Administration from San Francisco State University, and her JD from Golden Gate University School of Law.

ForSight Labs is a company focused on creating a community where innovation and practical application of ideas are combined to create companies focused on improving the lives of visually impaired patients. Since 2005, ForSight has started five companies focused on key needs in ophthalmology such as treatment of glaucoma and macular degeneration.

Prior to joining ForSight Labs, Ms. Macfarlane served as Chief Technology Counsel to The Foundry and as Technology Counsel for Thomas J. Fogarty, MD, where she participated in all aspects of early stage technology review, licensing, intellectual property management and company creation.

Ms. MacFarlane received her BA in Business Administration from San Francisco State University, and her JD from Golden Gate University School of Law.

Ed Mathers joined NEA as a Partner in August 2008 after spending 26 years working within the pharmaceutical/biotechnology industry in a variety of senior roles. Ed is focused on biotechnology and specialty pharmaceutical investments, and is a director of Envisia Therapeutics, Liquidia technologies, Lumos Pharmaceuticals, Mirna Therapeutics, Ra Pharmaceuticals, and Rhythm Pharmaceuticals.

Previously, Ed was a director of Plexxikon prior to its sale to Daiichi Sankyo. Ed is also a member of the Biotechnology Industry Organization (BIO) board and the NC State Physical and Mathematical Sciences Foundation board.

He earned his bachelor’s degree in chemistry from North Carolina State University.
Speakers, Moderators and Panelists

Cynthia Mattox, MD, FACS
Director of the Glaucoma and Cataract Service,
New England Eye Center
Associate Professor and Vice-Chair,
Department of Ophthalmology
Tufts University School of Medicine

Dr. Mattox recently completed her term as Associate Secretary for the American Academy of Ophthalmology (AAO) Annual Meeting, and has been a member of the Health Policy Committee since 2004. She is involved in the development of the IRIS Clinical Registry and chairs the Measure Development Taskforce. She has served on the American Glaucoma Society (AGS) Board since 2008, and serves as the Vice-President/President-Elect. Locally she is on the New England Ophthalmological Society’s Ophthalmic Services committee.

Along with her busy practice, Dr. Mattox trains Glaucoma fellows and Residents in glaucoma and cataract management and surgery, receiving the Resident Teaching Award three times. National awards include the 2014 Outstanding Advocate Award, the AAO’s Secretariat Award and Senior Achievement Award, and the AGS’ President’s Award.

J. Casey McGlynn, JD
Partner
Wilson Sonsini Goodrich & Rosati

Joining WSGR in 1978, Mr. McGlynn formed the Life Sciences Group in 1990, which is a nationally recognized leader in the representation of emerging growth companies in the life sciences field with a focus on Medical Devices, Digital Health and Biotech.

He assists his clients meet their financing needs through introductions to an extensive network of angel investors, financiers, venture capitalists, and more.

Mr. McGlynn was a founding member of BIO and served on its Emerging Company Board for over a decade. He is currently on the board of the Medical Device Manufacturing Association, an advocacy group for the Medtech industry. He is a founder of Life Science Angels, which has invested over $30 million in 40 life science companies, stimulating an additional $600 million from investors.

Eydie Miller-Ellis, MD
Professor of Clinical Ophthalmology
Director, Glaucoma Services
Scheie Eye Institute

While maintaining a busy glaucoma practice, Dr. Miller-Ellis lectures nationally and internationally on glaucoma diagnosis and management. She is a three-time recipient of the Surgical Teaching Award at the Scheie Eye Institute, Co-Vice chair of the American Academy of Ophthalmology’s (AAO) Ophthalmic Knowledge Base panel for glaucoma, chair of the AAO’s COMPASS panel for glaucoma, and 2008 recipient of the AAO Achievement Award. She’s Co-Director of the Rabb-Venable Research Program for the National Medical Association, Ophthalmology Section, past board member of the American Glaucoma Society and Women in Ophthalmology, and is currently President-Elect for the Joint Commission on Allied Health Personnel in Ophthalmology.

She received her AB in chemistry from Duke University, MD from the University of Pittsburgh, ophthalmology residency at UNC, Chapel Hill, and glaucoma fellowship at Yale.

Gary D. Novack, PhD
President
PharmaLogic Development, Inc.
Visiting Professor of Pharmacology and Ophthalmology, University of California Davis, School of Medicine

Dr. Novack is the founder and president of PharmaLogic Development, Inc.—a consultancy providing development expertise to pharmaceutical and medical device companies specializing in ophthalmology and other local therapies.

He has played a key role in the approval of over 40 ophthalmic products. He is a member of many professional societies, including the Glaucoma Research Society, and has served in leadership roles in the American society of clinical Pharmacology and Therapeutics.

Dr. Novack received his BA from the University of California Santa Cruz, his PhD in Pharmacology and Toxicology from the University of California Davis, and his postdoctoral fellowship in neurophysiology at the University of California Los Angeles. He earned his diploma in clinical pharmacology in 1990, the inaugural year of the certification.

Jane Rady
Divisional Vice President,
Business Development
Abbott Medical Optics Inc.

Prior to joining Abbott Medical Optics, Ms. Rady was a director and the Chief Executive Officer of Integrated Genomics, Inc., held senior positions within G.D. Searle & Co., and headed venture investing in Monsanto focusing on emerging technologies and businesses in biotechnology.

She serves as a board member on the University of California Irvine’s Biomedical Engineering Corporate Advisory Board, as a member of the board of directors for the Medical Device Manufacturer’s Association, is a board member of Ophthalmic Women Leaders, and chair of the Southern California chapter of Ophthalmic Women Leaders.

Ms. Rady began her career with Abbott Laboratories. She received her Bachelor and Master of Science from the University of Illinois in molecular biology/microbiology and her MBA from Northwestern’s Kellogg School of Management.
Speakers, Moderators and Panelists

Michael R. Robinson, MD  
Vice President, Clinical Development  
Translational Drug Delivery  
Allergan, Inc.

Michael R. Robinson, MD is a board-certified ophthalmologist who also completed 3 years of post-doctoral/fellowship training at the National Eye Institute. While at the National Eye Institute, Dr Robinson developed and patented the cyclosporine drug delivery system and conducted studies on patients with severe dry eye disease.

Dr. Robinson joined Allergan in 2005 and currently serves as Vice President—Clinical Development, Translational Drug Delivery. Given his broad clinical and research background, Dr. Robinson has served in multiple important roles at Allergan including Global Project Team Lead and Clinical Lead on projects related to ocular drug delivery in both the retina and glaucoma therapeutic areas.

Kuldev Singh, MD, MPH  
Professor of Ophthalmology and Director, Glaucoma Service  
Stanford University Medical Center

Dr. Singh has served as President of the American Glaucoma Society and Executive Vice President of the World Glaucoma Association. He is presently a Standing Member on the Medical Devices Advisory Committee of the U.S. Food and Drug Administration.

Dr. Singh received his MD and MPH degrees from the Johns Hopkins University School of Medicine and was an Eleanor Naylor Dana Charitable Trust Fellow at the Wilmer Eye Institute. He completed his ophthalmology residency at the Casey Eye Institute, Oregon Health and Science University followed by a Heed Foundation Fellowship focusing on glaucoma at the Bascom Palmer Eye Institute.

Thomas W. Samuelson, MD  
Attending Surgeon  
Minnesota Eye Consultants, P.A.  
Adjunct Associate Professor  
University of Minnesota

Dr. Samuelson specializes in glaucoma and anterior segment surgery. He received his subspecialty training in glaucoma at the Wills Eye Hospital in Philadelphia. He is a founding partner of Minnesota Eye Consultants in Minneapolis, Adjunct Associate Professor of Ophthalmology at the University of Minnesota, past President of the International Society of Spaeth Fellows/Wills Eye Hospital Glaucoma Fellows Society, and serves on the Governing Board of Directors of the American Glaucoma Society.

Dr. Samuelson is a past chairman of the ASCRS Glaucoma Clinical Advisory Committee and an Associate Secretariat for the AAO annual meeting.

Joel S. Schuman, MD, FACS  
Eye & Ear Foundation Professor  
Chairman, Department of Ophthalmology  
University of Pittsburgh

In his work at the University of Pittsburgh, Dr. Schuman’s group was the first to identify a molecular marker for human glaucoma, and he is an inventor of optical coherence tomography (OCT). He’s a founding member of the ARVO Multidisciplinary Ophthalmic Imaging cross-sectional group and of ARVO/isie.

In 2002 he received the Alcon Research Institute Award and the Lewis Rudin Glaucoma Prize, in 2006 the ARVO Translational Research Award, and in 2012 the Carnegie Science Center and Champalimaud Awards. In 2013 he gave the Robert N. Shaffer Lecture at the American Academy of Ophthalmology, and also received a Lifetime Achievement Honor Award from the AAO. He was named a Gold Fellow in the Association for Research in Vision and Ophthalmology Fellows Class of 2014.

Rohit Varma, MD, MPH  
Grace and Emery Beardsley Professor and Chair  
Department of Ophthalmology  
Director, USC Eye Institute  
Associate Dean for Strategic Planning/Network Development

Rohit Varma, MD, MPH is an expert in the epidemiology of eye diseases, and his primary research focuses on eye disease in the children and aging populations. He is also an expert on changes in the optic nerve in glaucoma and is studying new imaging techniques and devices in the early diagnosis and treatment of glaucomatous optic nerve damage.

Dr. Varma earned an MD from the University of Delhi, India and an MPH from Johns Hopkins University. He completed his residency at the Wilmer Eye Institute at Johns Hopkins Hospital and glaucoma fellowships at the Wills Eye Hospital, Philadelphia, and at the USC Department of Ophthalmology.

Tracy M. Valorie, BS, MBA  
Vice President, General Manager, Bausch + Lomb Pharmaceuticals

Ms. Valorie is the Vice President of Pharmaceutical Marketing at Bausch + Lomb and previous served as the Global Head of Glaucoma. Prior to joining B+L, Tracy was Pfizer’s Commercial Lead of Ophthalmology where she was responsible for marketed products (Xalabrands & Macugen), mid-stage development portfolio, and long range planning.

Her 20+ year career has included roles in discovery science, clinical development, early commercial assessment, marketing and strategic planning.

Ms. Valorie has held board membership seats at The Glaucoma Foundation and the ARVO Foundation for Eye Research.

Michael R. Robinson, MD

Kuldev Singh, MD, MPH

Thomas W. Samuelson, MD

Joel S. Schuman, MD, FACS

Rohit Varma, MD, MPH

Tracy M. Valorie, BS, MBA
Dr. Weinreb’s innovative glaucoma research ranges from the front to the back of the eye and from the clinic to the laboratory. His work has significantly impacted our understanding of the biology of glaucoma, as well as its diagnosis and management. His research also has developed cutting edge tools for basic science research and new discoveries that underly basic mechanisms of glaucoma.

He has served as President of the Association for Research in Vision and Ophthalmology (ARVO), President of the World Glaucoma Association (WGA), and President of the American Glaucoma Society. He is the current President of the Pan American Glaucoma Society.

Dr. Weinreb, MD, a graduate of Harvard Medical School, is a clinician, surgeon, educator, mentor and scientist.

Ruth D. Williams, MD
President,
Wheaton Eye Clinic

Dr. Williams is CEO of the Wheaton Eye Clinic, a 73-year-old ophthalmology practice that provides subspecialty eye care to more than 140,000 patients annually. She is a past president of the American Academy of Ophthalmology, representing ophthalmology at the AMA for nearly a decade and chairing its specialty section. After attending Rush Medical College, Dr. Williams completed an ophthalmology residency at California Pacific Medical Center in San Francisco and a glaucoma fellowship at Shaffer Associates and the University of California San Francisco.

Glaucoma:
“The Silent Thief of Sight”

We believe everyone should have the best possible vision throughout their lives. Alcon is dedicated to changing the glaucoma landscape through a focus on science, innovation, leadership, and partnership with healthcare professionals and patients around the world.

Alcon is committed to long-term investments in research and development to address unmet medical needs and advance the treatment of glaucoma in order to reduce the burden of disease around the world.

Visit MyEyes.com for additional tools and resources.
Founded in 1978 in San Francisco, Glaucoma Research Foundation was created to encourage innovative research to find better ways to care for people with glaucoma and ultimately find a cure.

Our Commitment to Education and Awareness
Glaucoma Research Foundation remains a principal source of information and support for doctors, patients and their families. We distribute more than 100,000 issues of our Gleams newsletter three times a year through the mail, by doctors’ offices and by email. Our website, www.glaucoma.org, helps over 3 million visitors annually with timely and accurate information. Our website and our educational booklet “Understanding and Living with Glaucoma” continue to be primary resources for patients seeking to learn more about their glaucoma diagnosis, treatment options, and Glaucoma Research Foundation’s research initiatives.

Speeding the Development of New Therapies
In February 2012, thanks to the leadership of Drs. Adrienne Graves and Andrew G. Iwach, we launched the Glaucoma 360 New Horizons Forum, an annual meeting dedicated to advancing the development of new glaucoma therapies and diagnostic devices. This unique gathering of medicine, industry, finance, and the FDA is a catalyst to advance novel ideas into clinical practice and assist patients in the near term. These innovative programs are made possible through generous philanthropic support. Glaucoma Research Foundation receives no government funding and, as good financial stewards, 84% of all funds raised go to funding research and education.

Please know that we are grateful for your participation in the fourth annual Glaucoma 360 and our efforts to eliminate this blinding disease.

Fostering Collaborative Research
For more than three decades, Glaucoma Research Foundation has funded pioneering and transformational studies to advance the field of glaucoma. An important funding priority is fostering collaborative research in order to speed the pace of discovery. Landmark projects include the Collaborative Normal Tension Glaucoma Study, the first controlled clinical trial to establish that lowering eye pressure preserves vision, and the establishment of the Catalyst for a Cure (CFC) research consortium.

Established in 2001, our first CFC team focused on neuroprotection and fundamentally changed how the scientific and medical communities view vision loss in glaucoma. Based on this successful model, the second CFC team was recruited and charged with identifying new biomarkers to indicate the earliest signs of glaucoma. The impact of this research will be valuable for both patients and doctors as it has the potential to transform how glaucoma is diagnosed and managed in the future.

Thomas M. Brunner
President and Chief Executive Officer
Glaucoma Research Foundation
Board of Directors

Board Chair
Andrew G. Iwach, MD
Glaucoma Center of San Francisco

President and Chief Executive Officer
Thomas M. Brunner
Glaucoma Research Foundation

Vice Chair
Robert L. Stamper, MD
UC San Francisco

Secretary
Bill Stewart
Apollo Programming Industries

Treasurer
Frederick H. Brinkmann
(Retired)

Directors
Timothy J. Dwyer
Private Investor
Adrienne L. Graves, PhD
Independent Director
John W. Grunden, PharmD
Merck & Co., Inc.
Rick Halprin, CPA
Alcon Laboratories, Inc.
Yehia Hashad, MD
Allergan, Inc.
John Hetherington, Jr., MD
UC San Francisco
H. Dunbar Hoskins, Jr., MD
American Academy of Ophthalmology (Retired)

Linda C. Linck
Delta Gamma Foundation
Dennis E. Singleton
Spieker Partners
Arthur S. Takahara
DeAnza Manufacturing Services, Inc.
Martin B. Wax, MD
PanOptica, Inc.
Charles Wilmoth
Wells Fargo Advisors, LLC.
Mona Zander
Mona and Ed Zander Family Foundation

Founder
Robert N. Shaffer, MD, FACS
(1912 – 2007)

Over a Decade of Excellence in Glaucoma Treatment

Lumenis supports the Glaucoma Research Foundation.

We wholeheartedly endorse the GRF mission “to prevent vision loss from glaucoma by investing in innovative research, education, and support with the ultimate goal of finding a cure.”

We’re proud to offer the most researched SLT laser therapy in the world used by many of the best ophthalmologists in the world.

Here’s how we care for glaucoma patients:
• Proven clinical outcomes
• Trusted technology
• Effective first line therapy

To learn more about Lumenis SLT, visit ophthalmic.lumenis.com/slt.
Save the Date!

January 29, 2016
San Francisco, CA

GLAUCOMA RESEARCH FOUNDATION
GLAUCOMA 360
NEW HORIZONS FORUM

2016

251 Post Street, Suite 600, San Francisco, CA 94108
Toll Free 800-826-6693   Tel 415-986-3162
Contact: events@glaucoma.org
www.glaucoma.org